Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer
C Liu, Y Li, X Xing, J Zhuang, J Wang, C Wang… - … Therapy-Nucleic Acids, 2022 - cell.com
Triple-negative breast cancer (TNBC) presented as high heterogeneous immunogenicity
that lacks useful clinical signatures to risk-stratify immune-benefit subtypes. We …
that lacks useful clinical signatures to risk-stratify immune-benefit subtypes. We …
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Abstract Purpose The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in
metastatic triple-negative breast cancer (TNBC). We strove to understand the biological …
metastatic triple-negative breast cancer (TNBC). We strove to understand the biological …
[HTML][HTML] Prognostic value of a glycolytic signature and its regulation by Y-Box-binding protein 1 in triple-negative breast cancer
YW Lai, WJ Hsu, WY Lee, CH Chen, YH Tsai, JZ Dai… - Cells, 2021 - mdpi.com
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as it
shows a high capacity for metastasis and poor prognoses. Metabolic reprogramming is one …
shows a high capacity for metastasis and poor prognoses. Metabolic reprogramming is one …
Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis
T Xu, J Liu, Y Xia, Z Wang, X Li, Q Gao - Annals of Medicine, 2021 - Taylor & Francis
Background The overall response rate of immunotherapy in triple-negative breast cancer
(TNBC) remains unsatisfactory. Accumulating evidence indicated that glucose metabolic …
(TNBC) remains unsatisfactory. Accumulating evidence indicated that glucose metabolic …
A molecular signature determines the prognostic and therapeutic subtype of non-muscle-invasive bladder cancer responsive to intravesical bacillus Calmette-Guérin …
SK Kim, SH Park, YU Kim, YJ Byun, XM Piao… - International Journal of …, 2021 - mdpi.com
Non-muscle-invasive bladder cancer (NMIBC) is clinically heterogeneous; thus, many
patients fail to respond to treatment and relapse. Here, we identified a molecular signature …
patients fail to respond to treatment and relapse. Here, we identified a molecular signature …
Transcriptomic characteristics according to tumor size and SUVmax in papillary thyroid cancer patients
SH Ju, SE Lee, S Yi, NR Choi, KH Kim, SM Kim… - Scientific Reports, 2024 - nature.com
The SUVmax is a measure of FDG uptake and is related with tumor aggressiveness in
thyroid cancer, however, its association with molecular pathways is unclear. Here, we …
thyroid cancer, however, its association with molecular pathways is unclear. Here, we …
Prognostic capacity of the transcriptional expression of lactate dehydrogenase A in patients with head and neck squamous cell carcinoma
Background To analyze the relationship between the transcriptional expression of lactate
dehydrogenase A (LDHA) and the disease control in patients with a head and squamous …
dehydrogenase A (LDHA) and the disease control in patients with a head and squamous …
Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux
Cells often alter metabolic strategies under nutrient-deprived conditions to support their
survival and growth. Characterizing metabolic reprogramming in the tumor …
survival and growth. Characterizing metabolic reprogramming in the tumor …
Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients
A Haghighat Jahromi, DA Barkauskas, M Zabel… - EJNMMI research, 2020 - Springer
Purpose Deriving links between imaging and genomic markers is an evolving field. 2-[18 F]
FDG PET/CT (18 F-fluorodeoxyglucose positron emission tomography–computed …
FDG PET/CT (18 F-fluorodeoxyglucose positron emission tomography–computed …
[HTML][HTML] Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast …
L Xu - Frontiers in Immunology, 2022 - frontiersin.org
Background Prior studies have highlighted that novel programmed cell death (PCD)
modalities, including ferroptosis, pyroptosis, and necroptosis, are correlated with tumor …
modalities, including ferroptosis, pyroptosis, and necroptosis, are correlated with tumor …